Sex and Racial Disparities in Outcomes of Transcatheter Edge-to-Edge Mitral Valve Repair for Functional Mitral Regurgitation: A Multicenter Prospective Analysis

经导管缘对缘二尖瓣修复术治疗功能性二尖瓣反流的疗效中性别和种族差异:一项多中心前瞻性分析

阅读:3

Abstract

BACKGROUND: Functional mitral regurgitation (FMR) is associated with poor heart failure (HF) outcomes. Mitral transcatheter edge-to-edge repair (M-TEER) is recommended for symptomatic patients despite medical therapy, though the influence of sex and race on outcomes remains understudied. METHODS: We analyzed Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapeutics registry data on patients undergoing M-TEER for FMR (November 2013 to December 2021). Primary outcomes were 30-day and 12-month all-cause and HF hospitalizations and mortality. Cox models adjusted for demographic and clinical variables. RESULTS: A total of 9441 patients were enrolled (57.4% male; 80.4% White, 16.3% Black, 2.7% Asian). Black patients were younger, had lower left ventricular (LV) ejection fraction, and had larger LV dimensions compared to White patients. They experienced lower 30-day procedural success rates (48.9% vs. 57.0%; p < 0.001) and higher adjusted 12-month HF hospitalizations (adjusted hazard ratio 1.35; 95% CI 1.09-1.67; p = 0.006). Asian patients generally demonstrated outcomes comparable to White patients. Female patients had higher baseline LV ejection fraction and smaller ventricular dimensions but demonstrated lower 30-day procedural success (48.1% vs. 61.3%; p < 0.001) and higher unadjusted 30-day readmission rates. However, adjusted 1-year outcomes were like males. CONCLUSIONS: Racial and sex disparities in M-TEER outcomes are evident. Black patients present with more advanced disease and experience lower procedural success and higher 12-month HF readmission rates compared to White. Female patients demonstrate lower procedural success but similar long-term adjusted outcomes compared to males. Efforts to address these disparities are essential to improving outcomes for all FMR patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。